Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,530
-590 (-4.18%)
May 20, 2026, 3:30 PM KST
Market Cap331.48B -6.6%
Revenue (ttm)3.76B +59.2%
Net Income-8.99B
EPS-374.27
Shares Out24.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume123,827
Average Volume115,083
Open14,120
Previous Close14,120
Day's Range13,360 - 14,120
52-Week Range11,390 - 33,300
Betan/a
RSI24.11
Earnings DateApr 2, 2026

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraTect-KRAS and AccuraTect... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2025, Genomictree's revenue was 3.76 billion, an increase of 59.17% compared to the previous year's 2.36 billion. Losses were -8.99 billion, -12.27% less than in 2024.

Financial Statements